RECRUITINGOBSERVATIONAL
Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT
Evaluation of Interferon-gamma Release Assays, Symptom Screening and Chest Radiograph for Detection of Subclinical Tuberculosis of End-stage Kidney Disease and Kidney Transplant Recipients in Thailand
About This Trial
This is an observational study among approximately 160 end-stage renal disease patients on renal replacement therapy and post-living donor or deceased donor kidney transplant recipients. Investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB/RIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.
Who May Be Eligible (Plain English)
Who May Qualify:
1. End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation
2. Aged more than or equal 18 years
Who Should NOT Join This Trial:
1. Positive PPD test or a previously documented positive PPD
2. Active pulmonary or extrapulmonary tuberculosis
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation
2. Aged more than or equal 18 years
Exclusion Criteria:
1. Positive PPD test or a previously documented positive PPD
2. Active pulmonary or extrapulmonary tuberculosis
Locations (1)
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand